新诊断癫痫患者的规范化药物治疗

Standardized medication strategy for new diagnosed epilepsy

目的评估新诊断癫痫患者的规范化药物治疗方法、疗效和安全性。方法对278例新诊断癫痫患者制订规范化药物治疗方法，在治疗24个月后评价疗效、保留率和安全性。结果278例新诊断患者中235例采用单药治疗，43例采用联合治疗。单药治疗以卡马西平和丙戊酸钠为主。24个月时总无发作率76．3％（212／278），有效率22．7％（63／278）。单药治疗保留率卡马西平为69．8％，丙戊酸钠为76．2％，奥卡西平为68．0％，托吡酯为69．6％，拉莫三嗪为83．3％，左乙拉西坦为85．7％，苯妥英钠为100％。结论患者经规范治疗后均得到满意的控制，表明规范治疗方法具有较好的临床实用价值，值得进一步推广。

Objective To formulate and detect the efficacy and safety of standardized medication strategy of epilepsy. Methods The normalized medication strategy was worked out in 278 new diagnosed patients, whose effect, retention rate and safety were evaluated after 24 months of treatment. Results Of all the 278 patients, 235 patients were taken mono-therapy while other 43 patients used therapeutic alliance. Most patients took CBZ or VPA as mono-therapy drugs. At the time after 24 months, almost 76. 3% （212/278） patients got seizure free, and the effectiveness was 22. 7% （63/278）. The retention rate of those mono-therapy drugs were investigated respectively. CBZ presented 69. 8% , VPA presented 76. 2% , OXC was 68.0%, TPM was 69. 6%, LTG was 83.3%, LEV presented 85.7%, and 100% for PHT. Conclusions All epileptic patients were well-controlled after taking standardized medication. The standardized medication strategy of epilepsy possesses valuable importance in clinical practice, which deserves further popularization.